NO20005155D0 - Forbedring av antistoff-cytokin fusjonsprotein medierte immunresponser ved ko-administrering med angiogenese inhibitor - Google Patents
Forbedring av antistoff-cytokin fusjonsprotein medierte immunresponser ved ko-administrering med angiogenese inhibitorInfo
- Publication number
- NO20005155D0 NO20005155D0 NO20005155A NO20005155A NO20005155D0 NO 20005155 D0 NO20005155 D0 NO 20005155D0 NO 20005155 A NO20005155 A NO 20005155A NO 20005155 A NO20005155 A NO 20005155A NO 20005155 D0 NO20005155 D0 NO 20005155D0
- Authority
- NO
- Norway
- Prior art keywords
- angiogenesis inhibitor
- antibody
- enhancement
- administration
- fusion protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8186398P | 1998-04-15 | 1998-04-15 | |
PCT/US1999/008335 WO1999052562A2 (en) | 1998-04-15 | 1999-04-15 | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20005155D0 true NO20005155D0 (no) | 2000-10-13 |
NO20005155L NO20005155L (no) | 2000-12-13 |
Family
ID=22166892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20005155A NO20005155L (no) | 1998-04-15 | 2000-10-13 | Forbedring av antistoff-cytokin fusjon protein-medierte immunoresponser ved ko-administrasjon med angiogeneseinhibator |
Country Status (19)
Country | Link |
---|---|
US (1) | US20040180035A1 (no) |
EP (1) | EP1071468B1 (no) |
JP (1) | JP2002511432A (no) |
CN (1) | CN1318092C (no) |
AT (1) | ATE329622T1 (no) |
AU (1) | AU758860B2 (no) |
BR (1) | BR9909583A (no) |
CA (1) | CA2328076C (no) |
CZ (1) | CZ20003767A3 (no) |
DE (1) | DE69931908T2 (no) |
ES (1) | ES2267263T3 (no) |
HK (1) | HK1038882A1 (no) |
HU (1) | HUP0101352A3 (no) |
MX (1) | MXPA00010070A (no) |
NO (1) | NO20005155L (no) |
PL (1) | PL343462A1 (no) |
RU (1) | RU2229305C2 (no) |
WO (1) | WO1999052562A2 (no) |
ZA (1) | ZA200005475B (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1037927T3 (da) * | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
CN101386651A (zh) * | 1998-08-25 | 2009-03-18 | 默克专利股份公司 | 表达以及分泌制管张素和内皮抑制素的免疫融合物 |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
RU2263118C2 (ru) * | 1999-08-09 | 2005-10-27 | Лексиген Фармасьютикэлс Корп. | Комплексы антител с несколькими цитокинами |
DE60135633D1 (de) | 2000-02-10 | 2008-10-16 | Massachusetts Eye & Ear Infirm | Photodynamische therapie zur behandlung von augenerkrankungen |
AU4314801A (en) | 2000-02-11 | 2001-08-20 | Lexigen Pharm Corp | Enhancing the circulating half-life of antibody-based fusion proteins |
EP1294401B1 (en) * | 2000-06-29 | 2007-08-01 | EMD Lexigen Research Center Corp. | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
US6911204B2 (en) | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
WO2002072605A2 (en) | 2001-03-07 | 2002-09-19 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
WO2002090566A2 (en) | 2001-05-03 | 2002-11-14 | Merck Patent Gmbh | Recombinant tumor specific antibody and use thereof |
BR0214650A (pt) | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
JP2008502317A (ja) * | 2003-12-30 | 2008-01-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Il−7融合タンパク質 |
CA2551916C (en) * | 2003-12-31 | 2014-04-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Fc-erythropoietin fusion protein with improved pharmacokinetics |
CA2552590A1 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
CA2553883C (en) | 2004-01-22 | 2013-04-02 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Anti-cancer antibodies with reduced complement fixation |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
CA2591297C (en) * | 2004-12-09 | 2015-01-13 | Stephen D. Gillies | Il-7 variants with reduced immunogenicity |
KR101030612B1 (ko) * | 2005-10-21 | 2011-04-20 | 에프. 호프만-라 로슈 아게 | 폴리펩타이드의 재조합 발현 방법 |
DK2270050T3 (da) | 2005-12-30 | 2013-08-12 | Merck Patent Gmbh | Anti-CD19-antistoffer med nedsat immunogenicitet |
EA015338B1 (ru) * | 2005-12-30 | 2011-06-30 | Мерк Патент Гмбх | ВАРИАНТЫ ИЛ-12p40 С УЛУЧШЕННОЙ СТАБИЛЬНОСТЬЮ |
GB2441789B (en) * | 2006-09-18 | 2012-03-28 | Angus Buchan Gordon | Use of a Tumour Volume Measuring Device |
SG175233A1 (en) | 2009-04-22 | 2011-11-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
EP2561888A1 (en) * | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CN104830901A (zh) * | 2015-01-21 | 2015-08-12 | 武汉友芝友生物制药有限公司 | 一种鼠肿瘤模型的构建方法及其应用 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
CN111094330A (zh) | 2017-07-03 | 2020-05-01 | 转矩医疗股份有限公司 | 编码免疫刺激融合分子的多核苷酸及其用途 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4469797A (en) * | 1982-09-23 | 1984-09-04 | Miles Laboratories, Inc. | Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
KR850004274A (ko) * | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5643565A (en) * | 1985-09-20 | 1997-07-01 | Chiron Corporation | Human IL-2 as a vaccine adjuvant |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5359035A (en) * | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5508031A (en) * | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
EP0307434B2 (en) * | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5120525A (en) * | 1988-03-29 | 1992-06-09 | Immunomedics, Inc. | Radiolabeled antibody cytotoxic therapy of cancer |
US5601819A (en) * | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US6750329B1 (en) * | 1989-05-05 | 2004-06-15 | Research Development Foundation | Antibody delivery system for biological response modifiers |
US6291158B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
EP0406857B1 (en) * | 1989-07-07 | 1995-05-24 | Takeda Chemical Industries, Ltd. | Proteins and production thereof |
US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
CA2082804A1 (en) * | 1990-07-27 | 1992-01-28 | Theodore Maione | Methods and compositions for treatment of angiogenic diseases |
CA2095836C (en) * | 1990-11-09 | 1999-04-06 | Stephen D. Gillies | Cytokine immunoconjugates |
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
US20020037558A1 (en) * | 1991-10-23 | 2002-03-28 | Kin-Ming Lo | E.coli produced immunoglobulin constructs |
US6627615B1 (en) * | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
DK0615451T3 (da) * | 1992-05-26 | 2006-04-24 | Immunex Corp | Hidtil ukendt cytokin der binder til CD30 |
US5614184A (en) * | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
ES2276390T3 (es) * | 1992-11-05 | 2007-06-16 | Sloan-Kettering Institute For Cancer Research | Antigeno de membrana especifico de la prostata. |
US5738849A (en) * | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US5543297A (en) * | 1992-12-22 | 1996-08-06 | Merck Frosst Canada, Inc. | Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5759551A (en) * | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
HUT73876A (en) * | 1993-04-29 | 1996-10-28 | Abbott Lab | Erythropoietin analog compositions and methods |
CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
NZ285501A (en) * | 1994-04-26 | 1998-02-26 | Childrens Medical Center | Plasminogen analogs (angiostatin), endothelial inhibitors, assays and kits |
US5639725A (en) * | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US5888773A (en) * | 1994-08-17 | 1999-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Method of producing single-chain Fv molecules |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
ES2167391T3 (es) * | 1994-09-16 | 2002-05-16 | Merck Patent Gmbh | Inmunoconjugados ii. |
US6485726B1 (en) * | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US5552524A (en) * | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5891680A (en) * | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
JP3342873B2 (ja) * | 1995-03-10 | 2002-11-11 | ジェネンテク・インコーポレイテッド | gas6による受容体活性化 |
US5719266A (en) * | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
PL324284A1 (en) * | 1995-06-30 | 1998-05-11 | Lilly Co Eli | Methods of treating diabetes |
US6406689B1 (en) * | 1995-10-03 | 2002-06-18 | Frank W. Falkenberg | Compositions and methods for treatment of tumors and metastatic diseases |
ES2206602T3 (es) * | 1995-10-23 | 2004-05-16 | The Children's Medical Center Corporation | Compuestos y metodos terapeuticos inhibidores de angiogenesis. |
US6620413B1 (en) * | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
CN1136197C (zh) * | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | 新的哒嗪酮衍生物 |
US5922685A (en) * | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
CA2258593A1 (en) * | 1996-07-02 | 1998-01-08 | Abraham Nudelman | Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
ATE218143T1 (de) * | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6171588B1 (en) * | 1997-04-11 | 2001-01-09 | G. D. Searle & Company | Anti-αvβ3 integrin antibody antagonists |
DK1037927T3 (da) * | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
CN1305387A (zh) * | 1998-04-17 | 2001-07-25 | 利思进药品公司 | 通过共同给予前列腺素抑制剂增强抗体-细胞因子融合蛋白介导的免疫应答 |
AU3655899A (en) * | 1998-04-20 | 1999-11-08 | Regents Of The University Of California, The | Modified immunoglobulin molecules and methods for use thereof |
US6620382B1 (en) * | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
CN101386651A (zh) * | 1998-08-25 | 2009-03-18 | 默克专利股份公司 | 表达以及分泌制管张素和内皮抑制素的免疫融合物 |
US6335176B1 (en) * | 1998-10-16 | 2002-01-01 | Pharmacopeia, Inc. | Incorporation of phosphorylation sites |
BR0007414A (pt) * | 1999-01-07 | 2001-10-16 | Lexigen Pharm Corp | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc |
US6348192B1 (en) * | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
BR0010725A (pt) * | 1999-05-19 | 2002-02-19 | Lexigen Pharm Corp | Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc |
PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
RU2263118C2 (ru) * | 1999-08-09 | 2005-10-27 | Лексиген Фармасьютикэлс Корп. | Комплексы антител с несколькими цитокинами |
US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
MXPA02011016A (es) * | 2000-05-12 | 2004-03-16 | Neose Technologies Inc | Glicopeptidos recombinantes de glucolisacion in vitro. |
EP1294401B1 (en) * | 2000-06-29 | 2007-08-01 | EMD Lexigen Research Center Corp. | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
CN1630720A (zh) * | 2001-01-18 | 2005-06-22 | 默克专利有限公司 | 具有葡糖脑苷脂酶活性的双功能融合蛋白 |
EP1998266A3 (en) * | 2001-02-19 | 2009-02-11 | Merck Patent GmbH | Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity |
KR20040074587A (ko) * | 2001-02-19 | 2004-08-25 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 인공 단백질 |
WO2002072605A2 (en) * | 2001-03-07 | 2002-09-19 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
WO2002090566A2 (en) * | 2001-05-03 | 2002-11-14 | Merck Patent Gmbh | Recombinant tumor specific antibody and use thereof |
BR0214650A (pt) * | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
-
1999
- 1999-04-15 CA CA002328076A patent/CA2328076C/en not_active Expired - Fee Related
- 1999-04-15 AT AT99917558T patent/ATE329622T1/de not_active IP Right Cessation
- 1999-04-15 ES ES99917558T patent/ES2267263T3/es not_active Expired - Lifetime
- 1999-04-15 AU AU35650/99A patent/AU758860B2/en not_active Ceased
- 1999-04-15 MX MXPA00010070A patent/MXPA00010070A/es active IP Right Grant
- 1999-04-15 WO PCT/US1999/008335 patent/WO1999052562A2/en active IP Right Grant
- 1999-04-15 HU HU0101352A patent/HUP0101352A3/hu unknown
- 1999-04-15 CZ CZ20003767A patent/CZ20003767A3/cs unknown
- 1999-04-15 JP JP2000543172A patent/JP2002511432A/ja not_active Withdrawn
- 1999-04-15 PL PL99343462A patent/PL343462A1/xx unknown
- 1999-04-15 CN CNB998072494A patent/CN1318092C/zh not_active Expired - Fee Related
- 1999-04-15 EP EP99917558A patent/EP1071468B1/en not_active Expired - Lifetime
- 1999-04-15 DE DE69931908T patent/DE69931908T2/de not_active Expired - Lifetime
- 1999-04-15 RU RU2000125521/15A patent/RU2229305C2/ru not_active IP Right Cessation
- 1999-04-15 BR BR9909583-1A patent/BR9909583A/pt not_active Application Discontinuation
-
2000
- 2000-10-06 ZA ZA200005475A patent/ZA200005475B/xx unknown
- 2000-10-13 NO NO20005155A patent/NO20005155L/no not_active Application Discontinuation
-
2002
- 2002-01-21 HK HK02100466.3A patent/HK1038882A1/zh unknown
-
2003
- 2003-11-14 US US10/714,165 patent/US20040180035A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2328076A1 (en) | 1999-10-21 |
AU3565099A (en) | 1999-11-01 |
ES2267263T3 (es) | 2007-03-01 |
WO1999052562A2 (en) | 1999-10-21 |
HUP0101352A3 (en) | 2003-08-28 |
US20040180035A1 (en) | 2004-09-16 |
EP1071468A2 (en) | 2001-01-31 |
ZA200005475B (en) | 2001-11-13 |
HK1038882A1 (zh) | 2002-04-04 |
MXPA00010070A (es) | 2004-03-10 |
ATE329622T1 (de) | 2006-07-15 |
RU2229305C2 (ru) | 2004-05-27 |
WO1999052562A3 (en) | 1999-11-18 |
CA2328076C (en) | 2009-10-06 |
HUP0101352A2 (hu) | 2001-08-28 |
EP1071468B1 (en) | 2006-06-14 |
BR9909583A (pt) | 2002-01-15 |
CN1318092C (zh) | 2007-05-30 |
AU758860B2 (en) | 2003-04-03 |
CZ20003767A3 (cs) | 2002-01-16 |
JP2002511432A (ja) | 2002-04-16 |
DE69931908D1 (de) | 2006-07-27 |
DE69931908T2 (de) | 2007-01-11 |
NO20005155L (no) | 2000-12-13 |
CN1305386A (zh) | 2001-07-25 |
PL343462A1 (en) | 2001-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20005155D0 (no) | Forbedring av antistoff-cytokin fusjonsprotein medierte immunresponser ved ko-administrering med angiogenese inhibitor | |
WO1999053958A3 (en) | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor | |
NO20026245D0 (no) | Forbedring av antistoff-cytokin-fusjonsprotein-formidlede immunresponser ved kombinert behandling med immunocytokin-opptaksökende midler | |
MXPA02012443A (es) | Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos. | |
EA200200097A1 (ru) | Имидазоимидазолы и триазолы в качестве противовоспалительных агентов | |
FI953748A (fi) | Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina | |
NO20024610D0 (no) | Synergistiske metoder og blandinger for behandling av kreft | |
PT1068870E (pt) | Agentes antitumorais | |
ES2169864T3 (es) | Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis. | |
ATE324444T1 (de) | Tek-antagonisten | |
NO924088L (no) | Antistoffer, fremgangsmaate for deres fremstilling og anvendelse dera v | |
DK2269656T3 (da) | Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer | |
EA200100732A1 (ru) | Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию | |
TR200201250T2 (tr) | Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri. | |
EA200200808A1 (ru) | Модифицированные цитокины, предназначенные для применения в терапии рака | |
ES2058343T3 (es) | Piridinas disubstituidas. | |
AP2000001984A0 (en) | Combination of protein farnesyltrandferase and HMG COA reductase inhibitors and their use to treat cancer. | |
ATE285247T1 (de) | Krebstherapie mit lymphotoxin | |
ES2181461T3 (es) | Utilizacion de nuevos agentes inductores de muerte celular en sinergia con interferones. | |
DK1162985T3 (da) | Matrixproteinsammensætninger til induktion af apoptose | |
DE69739167D1 (de) | Zusammensetzungen zur modulierung der länge von telomeren | |
DK1227826T3 (da) | Sammensætninger omfattende et ekstrakt af Perna canaliculus, methylsulfonylmethan og glucosamid samt anvendelsen heraf | |
DK1156795T3 (da) | Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens | |
DK0979093T3 (da) | Terapeutisk virusmiddel, hvis udvikling kan standses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |